To the Editor:

Coronary artery disease of the left main coronary artery (LMCA) is associated with poor clinical outcomes.[@bib1]^,^[@bib2] There are limited contemporary data from the United States on the outcomes of ST-segment elevation myocardial infarction (STEMI) of the LMCA.[@bib1], [@bib2], [@bib3] We conducted a study to address this issue.

Patients and Methods {#sec1}
====================

Using the National Inpatient Sample, admissions of patients with a primary STEMI diagnosis (*International Classification of Diseases, Tenth Revision, Clinical Modification* codes I21.x-22.x except I21.4, I22.Ax, I22.2, and I21.9) who underwent coronary angiography between January 1, 2016, and December 31, 2016, were identified. LMCA STEMI was identified by *International Classification of Diseases, Tenth Revision, Clinical Modification* code I21.01. Demographic characteristics, comorbidities, percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), and noncardiac procedures were identified as previously described.[@bib4] Outcomes of interest included in-hospital mortality, resource utilization, and management of LMCA STEMI. Survey procedures using discharge weights provided were used for national estimates. Multivariable regression was performed to identify predictors of in-hospital mortality. Statistical analyses were performed using SPSS Statistics for Windows, version 25.0 (IBM Corp).

Results {#sec2}
=======

During 2016, 159,860 patients with a primary STEMI diagnosis underwent diagnostic coronary angiography. Left main coronary artery involvement was noted in 410 (0.3%). Compared with the other patients, those with LMCA STEMI were older (67.1±11.9 vs 62.5±12.7 years), were more likely to have Medicare insurance (215 of 410 \[52.4%\] vs 67.607 of 159,450 \[42.4%\]), were more likely to be nonwhite (122 of 410 \[29.9%\] vs 37,152 of 159,450 \[23.3%\]), had higher comorbidity (mean Charlson comorbidity index, 3.9±2.3 vs 3.2±2.2), and were admitted to large hospitals (300 of 410 \[73.2%\] vs 92, 162 of 159,450 \[57.8%\]) (all *P*\<.001). The LMCA STEMI cohort had higher rates of acute organ failure, cardiogenic shock, cardiac arrest, mechanical circulatory support, and CABG use ([Table](#tbl1){ref-type="table"}). The cohort with LMCA STEMI had higher in-hospital mortality (76 of 410 \[18.5%\] vs 9,248 of 159,450 \[5.8%\]; unadjusted odds ratio \[OR\], 3.72; 95% CI, 2.90-4.79; *P*\<.001), longer hospital stay (7.9±7.9 vs 4.1±5.3 days), higher hospitalization costs (\$177,389±\$147,652 vs \$110,388±\$116,668), and fewer discharges to home (193 of 410 \[47.1%\] vs 123,574 of 159,450 \[77.5%\]; all *P*\<.001). In the LMCA STEMI cohort, the in-hospital mortality was higher for patients who underwent PCI (61 of 255 \[24.0%\]) compared with those who underwent CABG (5 of 130 \[3.8%\]). In patients with LMCA STEMI, female sex (OR, 12.33; 95% CI, 4.20-36.23), cardiogenic shock (OR, 6.84; 95% CI, 2.30-20.33), cardiac arrest (OR, 69.23; 95% CI, 22.91-209.15), and use of mechanical circulatory support (OR, 3.15; 95% CI, 1.18-8.40; all *P*\<.001), but not older age (\>75 years) (OR, 1.22; 95% CI, 0.51-2.94; *P*=.65), were independent predictors of in-hospital mortality.TableIn-Hospital Course and Management of STEMI Admissions[a](#dtbl1fna){ref-type="table-fn"}^,^[b](#dtbl1fnb){ref-type="table-fn"}In-hospital managementLMCA STEMI (N=410)Non-LMCA STEMI (N=159,450)*P* valueCardiac arrest70 (17.1)16,583 (10.4)\<.001Cardiogenic shock175 (42.7)19,772 (12.4)\<.001Acute organ dysfunction Respiratory135 (32.9)23,439 (14.7)\<.001 Renal105 (25.6)22,801 (14.3)\<.001 Hepatic25 (6.1)3,986 (2.5)\<.001 Hematologic60 (14.6)7,175 (4.5)\<.001 Neurologic35 (8.5)8,610 (5.4)\<.001Intravascular ultrasonography20 (4.9)7,335 (4.6).45Percutaneous coronary intervention255 (62.2)136,649 (85.7)\<.001Coronary artery bypass grafting130 (31.7)10,045 (6.3)\<.001Pulmonary artery catheterization30 (7.3)5,740 (3.6)\<.001Mechanical circulatory support IABP145 (35.4)14,191 (8.9)\<.001 Impella (Abiomed) heart pump50 (12.2)2,551 (1.6)\<.001 ECMO15 (3.7)478 (0.3)\<.001Invasive mechanical ventilation110 (26.8)16,264 (10.2)\<.001Noninvasive ventilation20 (4.9)2,073 (1.3)\<.001[^1][^2]

Discussion {#sec3}
==========

In this study, LMCA STEMI was associated with higher rates of cardiac arrest, cardiogenic shock, and acute organ failure and worse in-hospital outcomes. The patients with LMCA STEMI underwent PCI less frequently, and nearly one-third underwent CABG. Compared with previous studies, we noted lower rates of cardiac arrest and cardiogenic shock in this study.[@bib3] ST-segment elevation myocardial infarction from LMCA continues to have a high in-hospital and long-term mortality with only slight improvement in temporal trends.[@bib5] The optimal method of LMCA STEMI management remains to be defined and is largely determined by clinical acuity, coronary anatomy, and comorbidity. This study is limited by the use of an administrative database and lack of information on coronary anatomy, successful revascularization, and residual disease after PCI/CABG. In conclusion, LMCA STEMI is associated with high rates of cardiogenic shock, cardiac arrest, and acute organ failure. The outcomes of LMCA STEMI remain poor, and further research in this high-risk cohort is needed.
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[^1]: ECMO = extracorporeal membrane oxygenation; IABP = intra-aortic balloon pump; LMCA = left main coronary artery; STEMI = ST-segment elevation myocardial infarction.

[^2]: Data are presented as No. (percentage) of STEMI admissions.
